The GLP-1 telehealth category has expanded rapidly heading into 2026, with more consumers comparing pricing models, clinician access, and treatment formats than at any point since these programs first became widely available
For example, fusion proteins and RNA therapies can achieve extended half-lives or sustained protein production, reducing the dosing frequency and improving patient compliance
Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions including Stevens-Johnson syndrome
Sometimes, a plan that is difficult about Wegovy may have a more favorable view of another drug in the same class, especially if it's primarily for diabetes